Oncopeptides AB (publ) (Nasdaq Stockholm: ONCO), a biotech company focused on difficult-to-treat cancers, today announces the publication of new real-world data that further ...

BEIJING, CHINA / ACCESS Newswire / March 31, 2025 / CASI Pharmaceuticals, Inc. (NASDAQ:CASI), ("CASI" or the "Company"), a Cayman incorporated biopharmaceutical company focused on developing and comme ...

GSK had great expectations for Blenrep, which was approved in 2020 for multiple myeloma patients who have received at least four prior therapies – including an anti-CD38 monoclonal antibody ...

an immunomodulatory agent and an anti-CD38 monoclonal antibody, and has not previously received a BCMA therapy. A subgroup of patients with longer follow-up reported at this year's ASCO congress ...

CAR-T therapy for myeloma faces challenges in early-line use due to accessibility, eligibility criteria and long wait times, ...

However, induction therapy typically includes the following types of drugs: A four-drug regimen may also include an anti-CD38 monoclonal antibody. This drug helps your immune system target certain ...

They also had higher prior exposure to anti-CD38 monoclonal antibodies, as well as prior pomalidomide. Many of them were refractory to these drugs, and more patients in TRIMM-2 had extramedullary ...

The US Food and Drug Administration announced Thursday that it will be phasing out a requirement that monoclonal antibodies ...